Therefore, Turtle et al. conducted a phase I/II trial (NCT01865617) evaluating CD19-targeted BBζ CAR-T cell therapy for advanced CLL, ALL, and lymphoma, in which the T cell products were formulated in a defined 1:1 ratio of CD8+ and CD4+ T cell subsets (Turtle et al., 2016a). This evidence concerns the gene CD4 and acute lymphoblastic leukemia.